•
Dec 31, 2022

Welltower Q4 2022 Earnings Report

Announced Q4 2022 results, highlighted by significant SSNOI growth and strategic portfolio transitions.

Key Takeaways

Welltower reported a net loss of $0.01 per diluted share and normalized FFO of $0.83 per diluted share for Q4 2022. The company experienced strong same-store NOI growth, particularly in its Seniors Housing Operating portfolio, and made strategic moves to optimize its portfolio, including forming a joint venture with Integra Healthcare Properties.

Net loss attributable to common stockholders was $0.01 per diluted share.

Normalized FFO attributable to common stockholders was $0.83 per diluted share.

Total portfolio year-over-year same-store NOI grew by 12.9%, driven by a 28.1% increase in the Seniors Housing Operating portfolio.

Formed a joint venture with Integra Healthcare Properties and transitioned operations for skilled nursing assets previously managed by ProMedica.

Total Revenue
$1.52B
Previous year: $1.31B
+16.0%
EPS
$0.83
Previous year: $0.83
+0.0%
Normalized FFO
$404M
Gross Profit
$580M
Previous year: $524M
+10.6%
Cash and Equivalents
$632M
Previous year: $269M
+134.6%
Total Assets
$37.9B
Previous year: $34.9B
+8.5%

Welltower

Welltower

Forward Guidance

Welltower introduced its 2023 earnings guidance, projecting net income per share between $0.57 and $0.75 and normalized FFO per share between $3.35 and $3.53. The guidance assumes blended SSNOI growth of 8% to 13%.

Positive Outlook

  • Expect average blended SSNOI growth of 8% to 13%.
  • Seniors Housing Operating SSNOI growth approximately 15% to 24%.
  • Seniors Housing Triple-net SSNOI growth approximately 1% to 3%.
  • Outpatient Medical SSNOI growth approximately 2% to 3%.
  • Long-Term/Post-Acute Care SSNOI growth approximately 2% to 3%.

Challenges Ahead

  • Increased interest rates on floating rate debt.
  • Strengthening U.S. Dollar relative to the British Pound and Canadian Dollar are expected to reduce 2023 normalized FFO attributable to common stockholders by approximately $0.19 per diluted share versus 2022.
  • Earnings guidance includes only those acquisitions closed or announced to date.
  • No transitions or restructures beyond those announced to date are included.
  • Guidance does not include the recognition of any Provider Relief Funds or other government grants which may be received during the year.